Photo: Depositphotos
May 10, 2025, 14:14
Cizzle Bio Backs ALA’s Call for Broader Insurance Coverage of Biomarker Testing
Cizzle Bio shared on LinkedIn:
“The American Lung Association is advocating for broader insurance coverage for biomarker testing – a policy shift that could significantly enhance early lung cancer detection.
At Cizzle Bio, we stand behind this initiative. Our CIZ1B biomarker blood test offers a minimally invasive, accurate, and scalable solution to catch lung cancer early – when it’s most treatable.
Read how our work aligns with the ALA’s vision.”
Read article about Lung Cancer on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 10, 2025, 14:14
May 10, 2025, 14:11
May 10, 2025, 13:57